Searched for
PHARMA MAJOR LUPIN
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Mutual funds cut technology sector exposure to 8-year low in April. Is AI disruption reshaping sentiment?Mutual funds have significantly reduced their technology sector exposure to an eight-year low, driven by concerns over AI disruption, slowi...
- Doing more with less is India Inc's new mantra to beat tough timesPrioritising efficiency, Indian enterprises are reshaping their spending habits. Non-essential travel and expenses are being minimized, whi...
- Lupin launches generic anti-diabetic tablets in USPharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...
- Lupin gets tentative nod from USFDA for generic Sugammadex injectionLupin Ltd, a prominent name in the pharmaceutical world, revealed on Tuesday that it has gained tentative approval from the US health autho...
- Zydus, Lupin sign pact to co-market weight-loss Semaglutide injection in IndiaZydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...
- Lupin signs supply deal to launch antidepressant in CanadaDrug firm Lupin has partnered with Spektus Pharma. They will commercialise the antidepressant DeslaFlex in Canada. This collaboration combi...
- Lupin gets tentative nod from USFDA for generic HIV treatment drugLupin Ltd. has received tentative USFDA approval for its generic Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (50 mg/200 m...
- Lupin's arm gets UK regulator nod for COPD treatmentGlobal pharma major Lupin Limited on Friday announced that its UK subsidiary, Lupin Healthcare (UK) Limited, has received approval from the...
- Lupin acquires Australia's Southern Cross PharmaAs a part of the transaction, Lupin's Australia subsidiary Generic Health will gain access to over 60 registered products having sales of o...
- Experienced information security incident that affected select internal IT systems: LupinRestoration of the impacted systems is a priority and is underway, it added. The incident comes after another pharma major DrReddy's Labora...
- Lupin Q3 results: Loss widens to Rs 835 crore on higher taxTax expenses for the quarter jumped to Rs 767 crore from Rs 245.40 crore.
- Lupin gets EIR from USFDA for Nagpur facilityUSFDA conducted the inspection between August 5-8, 2019, Lupin said in a filing to the BSE.
- Pharma stocks unlikely to lead next leg of rally: Deepak ShenoySome midcap pharma companies though have come up with encouraging numbers, but overall this is a time to step back, says Shenoy.
- Lupin, Ranbaxy and Sun Pharma look pretty strong: Rajat BoseLupin continues to show major strength. So, Lupin, Ranbaxy and Sun Pharma are the stocks looking pretty good.
- Lupin targets buys in Gulf, Mexico, Brazil and ArgentinaLupin Ltd. continues its buying spree with planned acquisitions in Gulf, Mexico, Brazil and Argentina.
- Lupin sends notice to Oscient over cholesterol genericIndian pharma major Lupin has sent a legal notice to US-based Oscient Pharmaceuticals to inform them that they are seeking regulatory appro...
- Lupin to diversify into therapeutic segmentsAntibiotics and speciality domestic pharma major Lupin is planning to diversify into new therapeutic segments.
Load More
